Keeping up with Gene Editing - Monthly Roundups by Iris
Gene Editing news, once a month, in about five minutes: CRISPR gene editing, base and prime editing, in vivo gene editing therapies, gene editing clinical trials and approvals, delivery with lipid nanoparticles and AAV, and gene editing in agriculture. Every story links to its sources.
Latest: September 2026
FDA approves Ultragenyx's FAYUVI for MPS IIIA
- FDA approved Ultragenyx's FAYUVI, the first treatment for pediatric MPS IIIA.
- Patient-derived HSPCs reached up to 70% prime-editing efficiency for a GATA2 variant.
- EU rules now distinguish Category 1 and Category 2 new genomic techniques.
Want this for your field?
Iris builds a briefing agent around your own profile: your field, your focus areas, your context. Delivered on your schedule.